AtaiBeckley Inc. Common Stock (ATAI)
Healthcare – PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 99
- Market Cap
- $2.7B
About AtaiBeckley Inc. Common Stock
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
SentiSense also tracks daily options readings for AtaiBeckley Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
AtaiBeckley Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.